Rohit Parmar, MD
Nuclear Cardiology · Dallas, TXNPI 1114985405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $828 and has fallen 63.4% since, to $303 in 2025.
Across 188 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$746
- Amgen$513
- Pfizer$356
- E.r. Squibb & Sons, L.L.C.$289
- Heartflow, Inc.$168
- Medtronic$163
- plus $932 from 17 others
What the payments were for
- Food & beverage$3,156100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 60 | $746 |
| Amgen | 33 | $513 |
| Pfizer | 20 | $356 |
| E.r. Squibb & Sons, L.L.C. | 16 | $289 |
| Heartflow, Inc. | 3 | $168 |
| Medtronic | 2 | $163 |
| Novo Nordisk | 7 | $137 |
| Philips North America LLC | 7 | $128 |
| Merck | 7 | $110 |
| Johnson & Johnson | 6 | $93 |
| Boehringer Ingelheim | 4 | $77 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $76 |
| Amarin Pharma, Inc. | 4 | $75 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $68 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Vital Connect, Inc | 1 | $17 |
| Cvrx, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Edwards Lifesciences | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$139
- COREVALVE EVOLUT R$139
How this compares
Too few nuclear cardiology providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 468 | $499,165 |
| Repatha SureclickEvolocumab | 133 | $138,634 |
| EntrestoSacubitril/Valsartan | 99 | $134,367 |
| XareltoRivaroxaban | 77 | $78,848 |
| JardianceEmpagliflozin | 34 | $46,095 |
| Praluent PenAlirocumab | 53 | $33,797 |
| FarxigaDapagliflozin Propanediol | 21 | $23,761 |
| Metoprolol Succinate | 508 | $6,731 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 163 | $5,610 |
| Atorvastatin Calcium | 398 | $4,212 |
| Rosuvastatin Calcium | 336 | $4,171 |
| Carvedilol | 346 | $3,120 |
| Flecainide Acetate | 35 | $2,190 |
| ClopidogrelClopidogrel Bisulfate | 143 | $1,808 |
| Losartan Potassium | 155 | $1,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $356 | $499,165468 claims |
| NovartisEntresto | $746 | $134,36799 claims |
| Johnson & JohnsonXarelto | $93 | $78,84877 claims |
| Boehringer IngelheimJardiance | $77 | $46,09534 claims |
| AstraZenecaFarxiga | $15 | $23,76121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Texason file to place this against a meaningful peer group, so we don't.
Other nuclear cardiology in Dallas
- John HoDallas$83
- James AtkinsDallas$36
- Brandy WalkerDallas$22
- Randall WilsonDallas$18
- Nina RadfordDallas$12
- Dongxia FengTemple$408
- Samuel LewisFrisco$169
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.